Mavrilimumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mavrilimumab
DrugBank Accession Number
DB12534
Background

Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • CAM-3001
  • Mavrilimumab

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Mavrilimumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Mavrilimumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Mavrilimumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Mavrilimumab.
AmivantamabThe risk or severity of adverse effects can be increased when Mavrilimumab is combined with Amivantamab.
AnsuvimabThe risk or severity of adverse effects can be increased when Mavrilimumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Mavrilimumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Mavrilimumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mavrilimumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1158JD1P9A
CAS number
1085337-57-0

References

General References
Not Available
PubChem Substance
347911343
Wikipedia
Mavrilimumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Pneumonia1
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Pneumonia1
2CompletedTreatmentGiant Cell Arteritis (GCA)1
2CompletedTreatmentRheumatoid Arthritis3
2Not Yet RecruitingTreatmentAcute Respiratory Failure / ARDS, Human / Coronavirus Disease 2019 (COVID‑19) / Viral Pneumonia1
2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Pneumonia1
2TerminatedTreatmentRheumatoid Arthritis1
2, 3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID1
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 22:45 / Updated on February 21, 2021 18:53